Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05443724 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 700
- Enrollment target
NCT05443724 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 700 participants.
The verdict
NCT05443724, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 700 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
Interventions
- DRUG CVL-231 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2022-09-02 |
| Est. Completion | 2025-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05443724
The ClinicalTrials.gov registry entry for NCT05443724 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CVL-231 30 mg is the first listed.
NCT05443724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05443724 about?
NCT05443724 is a clinical study titled "A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia". The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
What is the current status of trial NCT05443724?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 700 participants. The study started on 2022-09-02. Estimated completion is 2025-06-25.
What interventions are being tested in trial NCT05443724?
The interventions under investigation include: CVL-231 30 mg (DRUG).
Who is sponsoring clinical trial NCT05443724?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.